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Orexins and Orexin Receptors: A Family of
Hypothalamic Neuropeptides and G Protein-Coupled
Receptors that Regulate Feeding Behavior
lipids, peptides, and proteases. Ligand binding initiates
intracellular signal transduction through the activation
of heterotrimeric G proteins. All of the known small regu-
latory peptides (small peptide hormones and neuropep-
tides) exert their biological actions by acting on GPCRs.
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prepro-orexin mRNA and immunoreactive orexin-A Purification and Structure of Orexins
are localized in neurons within and around the lateral Our general strategy was to screen high-resolution HPLC
and posterior hypothalamus in the adult rat brain. fractions of various tissue extracts for GPCR-agonist
When administered centrally to rats, these peptides activity, using multiple orphan GPCR±expressing cell
stimulate food consumption. prepro-orexin mRNA lines tested in parallel. For this purpose, we generated
level is up-regulated upon fasting, suggesting a physi- over 50 stable transfectant cell lines, each expressing
ological role for the peptides as mediators in the cen- a distinct orphan GPCR cDNA, which can be used as
tral feedback mechanism that regulates feeding be- reporter cell lines in order to identify endogenous ligands
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fractions derived from tissue extracts and we monitored
a number of signal transduction read-outs for hetero-
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Figure 1. Purification of Endogenous Ligands for the Orphan Receptor HFGAN72 (OX1R)
(A) Activation of the HFGAN72 receptor in transfected HEK293 cells by reverse-phase HPLC fractions of crude peptide extracts from rat brain.
Top panel, chromatogram. Acetonitrile gradient and absorbance of eluted materials are indicated by solid and dotted lines, respectively.
Middle and bottom panels, [Ca21]i transients in two HEK293 cell lines stably expressing unrelated orphan receptors HFGAN72 and HPRAJ70,
respectively. Peak increments in [Ca21]i evoked by designated HPLC fractions are normalized against the response induced by 100 nM
endothelin-1 in the same reporter cell preparations and plotted as relative activity. Note that a number of fractions induced similar responses
in both cell lines, presumably by acting on endogenous receptors in the host HEK293 cells. However, fractions 60±61 (marked as A; containing
orexin-A) induced robust [Ca21]i transients in HFGAN72-transfected cells but not in HPRAJ70-transfected cells. Fractions 56 and 58 also
exhibited weaker but distinct activities specific to HFGAN72 (marked as B and B9; containing orexin-B and orexin-B[3±28], respectively).
(B) Cation exchange HPLC of fractions 60±61 from Figure 1A. Bars show normalized magnitude of [Ca21]i in HFGAN72±expressing HEK293
cells as in Figure 1A.
(C) Reverse-phase HPLC of active fractions from Figure 1B.
(D) Final purification by reverse-phase HPLC at 408C of active fractions in Figure 1C. Arrow, final orexin-A peak.
termed HFGAN72. This receptor was initially identified acid-acetone extracts of rat brains by collecting active
fractions after four steps of HPLC (Figure 1). The finalas an expressed sequence tag (EST) from human brain
(see Figure 2C). A major activity peak (marked ªAº in purified material, corresponding to the absorbancepeak
at the arrow in Figure 1D, was subjected to structuralFigure 1A) was reproducibly accompanied by two addi-
tional minor peaks of activity (B and B9 in Figure 1A). analyses by limited protease digestions followed by
nanoelectrospray tandem mass spectrometry, EdmanThese activities appeared to be specific for the HFGAN72
receptor, since the active fractions failed to evoke de- degradation, and MALDI mass spectrometry (see Exper-
imental Procedures for details). The active substance,tectable [Ca21]i transients in cells expressing an unre-
lated orphan receptor, HPRAJ70, in a parallel assay (Fig- termed orexin-A, was found to be a 33±amino acid pep-
tide of 3,562 Da, with an N-terminalpyroglutamyl residueure 1A). These activities seemed to be peptidic, since
protease treatment of the active fractions destroyed the and C-terminal amidation (Figure 2A). Molecular mass of
the peptide as well as its sequencing analyses indicatedactivity.
We purified the major activity to homogeneity from that the four Cys residues of orexin-A formed two sets of
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Figure 2. Amino Acid Sequences of Orexins and Orexin Receptors
(A) Structures of mature orexin-A and -B peptides. The topology of the two intrachain disulfide bonds in orexin-A is indicated above the
sequence. The N-terminal pyroglutamyl residue (,E) in orexin-A is depicted. Amino acid identities are indicated by boxes. Asterisks indicate
that human and mouse sequences are deduced from the respective genomic sequences and not from purified peptides.
(B) Deduced amino acid sequences of prepro-orexin precursor polypeptides. Orexin-A and -B sequences are boxed. Secretory signal sequences
predicated by the SignalP Server (http://www.cbs.dtu.dk/services/SignalP/) are marked by equal signs (5); prohormone convertase cleavage
and amidation sites by asterisks (*). Interspecifically identical residues are indicated by vertical bars. The full-length nucleotide sequences of
human, rat, and mouse prepro-orexin cDNAs have been submitted to GenBank (accession numbers AF041240, AF041241, and AF041242).
(C) Deduced amino acid sequences of rat (r) and human (h) OX1 and OX2 receptors. Amino acid residues that are identical in all four sequences
are boxed. Putative transmembrane (TM) domains are marked above the aligned sequences, as predicted by the PredictProtein server (http://
www.embl-heidelberg.de/predictprotein). Gaps introduced to obtain optimal alignment are indicated by dashes. The full-length nucleotide
sequences of human and rat orexin receptor cDNAs have been submitted to GenBank (accession numbers AF041243, AF041244, AF041245,
and AF041246).
intrachain disulfide bonds. The topology of the disulfide The peptide, termed orexin-B, was 46% (13/28) identical
in sequence to orexin-A (Figure 2A). Peak B9 containedbonds was determined by selectively synthesizing the
peptides with different disulfide topologies by using se- an N-terminally truncated [des Arg-Pro]orexin-B, which
we designate orexin-B[3±28]. Further investigation is re-lective deprotection and sequential oxidation of two of
the four Cys residues and then comparing these syn- quired to determine whether this truncation represents
a physiologically relevant processing or whether it is athetic peptides with purified natural orexin-A in isocratic
reverse-phase HPLC. The topology was determined to result of an artifactual proteolysis during the extraction
procedure. In the subsequent studies described below,be [Cys6-Cys12, Cys7-Cys14] (Figure 2A). Using similar
protocols, we also purified the analogous activity from only orexin-A and full-length orexin-B were subjected
to further biological characterization.bovine hypothalamic extracts, and we found that the
structure of bovine orexin-A was identical to that of the
rat peptide. Structure of the Prepro-Orexin Precursor
The amino acid sequences of purified orexin-A and -BIn addition to the major peak of activity, the HPLC
fractions contained two minor activity peaks that we exhibited no meaningful similarity to any known pep-
tides. A BLAST search of the GenBank database alsodesignated B and B9 (Figure 1A). We isolated peptides
responsible for both of these activities from rat brain failed to detect an entry that contains these or similar
sequences. Therefore, we sought to isolate the cDNAextracts using similar purification protocols (see Experi-
mental Procedures). Mass spectrometry and Edman se- encoding the precursor polypeptide; we first obtained
a cDNAfragment encoding a part of orexin-Aby RT±PCRquencing showed that peak B contained a 28±amino
acid, C-terminally amidated linear peptide of 2,937 Da. of rat brain mRNA, using highly degenerate primers
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Figure 3. Pharmacological Characterization
of Synthetic Human Orexins on Human Or-
exin Receptors Expressed in Stably Trans-
fected CHO Cells
(A and B) Competitive radioligand binding
assays. Displacement of [125I-Tyr17]orexin-A
binding to cells expressing human OX1R (A)
and OX2R (B) by increasing concentrations of
unlabeled orexin-A (open circle) and human
orexin-B (filled circle) are determined in qua-
druplicates. Level of nonspecific binding was
approximately 20% of the binding in the ab-
sence of competitor.
(C and D) Dose-response relationships of
[Ca21]i transients evoked by orexin-A (open
circle) and human orexin-B (filled circle) in
cells expressing human OX1R (C) and OX2R
(D). Peak [Ca21]i values are determined in du-
plicates.
based on parts of the orexin-A sequence. We then per- residue is again followed by Gly-Arg-Arg, a C-terminal
amidation signal, consistent with our finding that orexin-Bformed 59-RACE and 39-RACE reactions to obtain the
full-length cDNA. We found that this cDNA encoded is also C-terminally amidated.
We isolated human and mouse genomic fragmentsboth orexin-A and -B (Figures 2A and 2B).
The 59-mostATG codon of the 585 bp cDNA (GenBank containing the prepro-orexin gene in order to predict
the sequences of the human and mouse prepro-orexinaccession number AF041241) was preceded by an in-
frame stop codon, and the sequence around this initia- polypeptides. Details of the gene structure will be re-
ported elsewhere. The predicted human and mouse or-tion codon conformed to Kozak's rules. The open read-
ing frame starting with this ATG encodes a 130-residue exin-A sequences were both identical to rat and bovine
orexin-A (Figure 2A). Mouse orexin-B was also predictedpolypeptide, the rat prepro-orexin (Figure 2B). The first
33 amino acids exhibited characteristics of a secretory to be identical to rat orexin-B. Human orexin-B had
two amino acid substitutions when compared with thesignal sequence: a hydrophobic core followed by resi-
dues with small polar side chains (von Heijne, 1986). rodent sequence (Figure 2A). Overall, the human and
mouse prepro-orexin sequences were 83% and 95%The SignalP Server web site predicted that Ala32-Gln33
was the most likely site for signal sequence cleavage. identical to their rat counterparts, respectively. A ma-
jority of amino acid substitutions were found in theThe orexin-A sequence starts with Gln33, which is pre-
sumably cyclized enzymatically into the N-terminal py- C-terminal part of the precursor, which appears unlikely
to encode for another bioactive peptide.roglutamyl residue by transamidation (Busby et al., 1987;
Bateman et al., 1990). Thus, the mature peptide directly Radiation hybrid mapping showed that the human
prepro-orexin gene is most tightly linked to the MIT STSfollows the signal peptide cleavage site. The last residue
of the mature peptide is followed by Gly66, which pre- markers WI-6595 and UTR9641. The inferred cytoge-
netic location between these markers is 17q21. Interest-sumably serves as NH2 donor for C-terminal amidation
by sequential actions of peptidylglycine monooxygenase ingly, the localization at chromosome 17q21 raises the
possibility that the prepro-orexin gene may be a candi-and peptidylamidoglycolate lyase (Bradbury and Smyth,
1991; Eipper et al., 1993). As expected, Gly66 is followed date gene for a group of neurodegenerative disorders
collectively called ªchromosome 17-linked dementiaºby a pair of basic amino acid residues, Lys67-Arg68,
which constitute a recognition site for prohormone con- (Wilhelmsen, 1997), including nosological entities such
as disinhibition-dementia-parkinsonism-amyotrophy com-vertases (Rouille et al., 1995). The next segment of the
deduced prepro-orexin sequence, Arg69-Met96, was plex (DDPAC; MIM No. *600274) and pallido-ponto-
nigral degeneration (PPND; MIM No. *168610), whichidentical to thesequence of purified orexin-B. The Met96
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may be caused by allelic mutations. Both DDPAC and
PPND have recently been mapped to 17q21±22 (Wil-
helmsen et al., 1994; Wijker et al., 1996).
Characterization of Orexin Receptors
Figure 2C shows the deduced amino acid sequences
of the original HFGAN72 receptor, which we now call
OX1 receptor (OX1R). Among various classes of GPCR,
OX1R is structurally most similar to certain neuropeptide
receptors, most notably to the Y2 neuropeptide Y (NPY)
receptor (26% identity), followed by the TRH receptor,
cholesystokinin type-A receptor, and NK2 neurokinin
receptor (25%, 23%, and 20% identity, respectively).
This is consistent with our hypothesis that OX1R is the
receptor for orexins, another class of small regulatory
peptides. In order to characterize further their pharma-
cological interactions, we performed in vitro functional
assays using transfected cell lines expressing the recep-
tor. Mock transfected CHO cells did not exhibit detect-
able levels of specific binding of radio-iodinated [125I-
Tyr17]orexin-A. Stable transfection of CHO cells with an
expression vector containing the human OX1R cDNA Figure 4. Tissue Distribution of Rat prepro-orexin and Orexin Re-
(CHO/OX1R) conferred the ability to bind [125I]orexin-A ceptor mRNAs
(Figure 3A).The radioligand binding was inhibited by nano- A membrane containing z2 mg/lane of poly(A)1 RNA from indicated
rat tissues (Clontech, cat. no. 7764±1) was sequentially rehybridizedmolar concentrations of unlabeled synthetic orexin-A in
with designated cDNA probes using standard methods. Sizes ofa dose-dependent manner, but not by any of several
prepro-orexin, OX1R and OX2R mRNAs are approximately 0.7, 2.5,unrelated peptides tested, including human NPY and
and 3.5 kb, respectively (arrowheads). A segment of rat prepro-
endothelin-1 at up to 10 mM (data not shown). The con- orexin cDNA encoding Gln33-Ser128 (Figure 2B) as well as full-
centration of unlabeled orexin-A required to displace length rat OX1R and OX2R cDNAs (Figure 2C) were used as probes.
50% of specific radioligand binding (IC50) was 20 nM as These probes do not detectably cross-hybridize with each other
under the high-stringency conditions used. Autoradiography wascalculated by the LIGAND program (Munson and Rod-
exposed for 5 days, 3 days, 3 days and 3 hr for prepro-orexin, OX1R,bard, 1980). Orexin-A also induced a transient increase
OX2R, and b-actin probes.in [Ca21]i in CHO/OX1R cells in a dose-dependent man-
ner (Figure 3C), but failed to induce detectable [Ca21]i
transients in mock transfected CHO cells. We feel that
showed much higher similarities to the OX1R sequencethe calcium mobilization is likely caused by the activa-
than to numerous other GPCR entries. At the nucleotidetion of the Gq class of heterotrimeric G proteins (Hepler
sequence level, they differed enough from the humanet al., 1994). The calculated concentration of orexin-A
OX1R cDNA sequence to indicate that they are not de-required to induce half-maximum response (EC50) was
rived from the OX1R gene itself. We subsequently found30 nM. We obtained similar results in radioligand bind-
that these two ESTs were derived from 59 and 39 parts ofing and [Ca21]i transient assays performed with stably
the same transcript. Full-length cloning and sequencingtransfected HEK293 cells (data not shown). These find-
showed that this cDNA encodes a GPCR, termed OX2R,ings confirm that orexin-A is indeed a specific, high-
that highly resembles OX1R (Figure 2C). The amino acidaffinity agonist for OX1R.
identity between the deduced full-length human OX1RAs expected from our purification experiments, syn-
and OX2R sequences is 64%. Thus, these receptors arethetic human orexin-B also acted as a specific agonist
much more similar to each other than they are to otheron CHO/OX1R cells in a parallel set of experiments (Fig-
GPCRs. Amino acid identities between the human andures 3A and 3C). Interestingly, however, we found that
rat homologs of each of these receptors are 94% forhuman orexin-B has significantly lower affinity for the
OX1R and 95% for OX2R, indicating that both receptorhuman OX1R: the calculated IC50 in the competitive bind-
genes are highly conserved between the species.ing assay and the EC50 in the [Ca21]i transient assay were
To characterize functionally the OX2R further, we re-420 nM and 2500 nM for human orexin-B, respectively,
peated competitive radioligand binding assays andindicating 2±3 orders of magnitude lower affinities as
[Ca21]i transient dose-response studies using stablycompared with orexin-A. Similar results were obtained
transfected CHO cells expressing the human OX2Rwith HEK293 cells expressing OX1R.
cDNA. The results demonstrated that OX2R is indeed aThe findings with orexin-B led us to suspect that there
high-affinity receptor for human orexin-B, with an IC50is an additional orexin receptor(s) for which orexin-B has
of 36 nM in the binding assay and an EC50 of 60 nM inhigh affinity. A BLAST (tblastn) search of the GenBank
the [Ca21]i transient assay (Figures 3B and 3D). Orexin-AdbEST database with the OX1R amino acid sequence
also had high affinity for this receptor, with 38 nM IC50detected two highly similar EST entries: accession num-
and 34 nM EC50 values, which are similar to the values forbers D81887 (human fetal brain cDNA) and W86548 (hu-
man fetal liver/spleen cDNA). These EST sequences orexin-B. Thus, we conclude that OX2R is a nonselective
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Figure 5. Localization of prepro-orexin mRNA and Immunoreactive Peptide in Adult Rat Brain
(A) Visualization of neurons containing prepro-orexin mRNA in the adult rat hypo- and subthalamic areas by in situ hybridization. Coronal
section of brain hybridized with 35S-labeled anti-sense riboprobe showing the bilateral and symmetrical distribution of labeled neurons. No
detectable signal beyond background was generated by sense riboprobe. The yellow rectangle designates the area schematized in Figure 5B.
(B) prepro-orexin mRNA±containing neurons are shown in red superimposed upon anatomical structures of the hypo- and subthalamic areas
(Paxinos and Watson, 1986): lateral hypothalamic area (LH), perifornical nucleus (PeF), posterior hypothalamic area (PH), subthalamic nucleus
(Sth), subincertal nucleus (SubI), and ventral zona incerta (ZIV). Additional landmarks include: thalamus (THAL), habenular complex (HAB),
internal capsule (ic), optic tract (opt), mammillothalamic tract (mt), fornix (f), medial forebrain bundle (mfb), third ventricle (3V), arcuate
hypothalamic nucleus (Arc), dorsomedial hypothalamic nucleus (DM), and ventromedial hypothalamic nucleus (VMH). (Permission for use
granted by Academic Press.)
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receptor for both orexin-A and -B, while OX1R is selec- brain (Figures 5A±5D). In the hypothalamus, positive
neurons were found in the lateral (Figures 5A±5H) andtive for orexin-A.
In radiation hybrid mapping, the MIT markers showing posterior hypothalamic areas (Figures 5A±5F) and the
perifornical nucleus (Figures 5C±5F). In the subthalamustightest linkage to the human OX1R and OX2R genes are
the STS markers D1S195 and D1S443, and WI-5448 and (also called ventral thalamus), the zona incerta, subin-
certal, and subthalamic nuclei were positive (Figure 5B).CHLC.GATA74F07, respectively. The inferred cytoge-
netic locations between these markers are 1p33 for Both in situ hybridization histochemistry (Figures 5A and
5C±5F) and immunofluorescent cytochemistry labeledOX1R, and 6cen (p11-q11) for OX2R (accurate cytoge-
netic locations are often difficult to interpret from radia- the cytoplasm of medium-sized neurons (Figures 5D±
5H), showing identical distributions. The shapes of thetion hybrid maps in which the gene lies near the cen-
tromere). neurons varied from thin and fusiform to robust and
multipolar. It is noteworthy that no signal was detected
in neurons of the paraventricular (not shown), ventrome-Tissue Distribution of Orexin and Orexin Receptors
dial (Figure 5B), or arcuate nuclei (Figure 5B), which areN-terminal pyroglutamyl cyclization (seen in orexin-A)
known to contain a variety of neuropeptides associatedas well as C-terminal amidation (both orexin-A and -B)
with food consumption (Bernardis and Bellinger, 1996;are posttranslational modifications that are most often
Bing et al., 1996; see below).found in neuropeptides. Northern blot analysis of adult
rat tissues showed that the 0.7 kb prepro-orexin mRNA
is detected exclusively in the brain except, in a small Stimulation of Feeding Behavior by Centrally
amount, in the testis (Figure 4). In adult rats, OX1R and Administered Orexins
OX2R mRNAs were also detected exclusively in the brain The lateral hypothalamic area has been implicated in the
(Figure 4). These findings are consistent with the idea regulation of feeding behavior and energy homeostasis
that orexins are regulatory peptides that function within ever since the classic experiments showing that animals
the central nervous system. with lateral hypothalamic lesions had decreased food
Preliminary Northern blot analysis of human mRNA intake and lower ªset pointº for body weight (Oomura,
from multiple brain regions (human brain blots II and III, 1980; Bernardis and Bellinger, 1993, 1996). The striking
Clontech) demonstrated that the prepro-orexin mRNA localization of orexin±containing neurons in the lateral
was expressed abundantly in subthalamic nucleus, but hypothalamus and some of its adjacent areas suggested
undetectable in other brain regions tested (data not to us the possibility that the neuropeptide may be in-
shown; hypothalamus was not included in these brain volved in the regulation of food intake. To evaluate this
blots). prepro-orexin mRNA was also undetectable in hypothesis, we administered orexin acutely into the lat-
the human heart, placenta, lung, liver, skeletal muscle, eral ventricle of male rats through preimplanted indwell-
kidney, and pancreas (data not shown). These findings ing catheters. When a bolus was administered intracere-
are consistent with the results of the in situ hybridization broventricularly in early light phase, orexin-A stimulated
in the rat brain described below. food consumption in a dose-dependent manner within
1 hr (Figure 6, left). The magnitudes of stimulation with
3 nmol and 30 nmol orexin-A the 2 hr time point wereDistribution of Orexin±Containing
Neurons in Rat Brain 6- and 10-fold, respectively. The effect persisted at 4 h;
the amount of food consumed during the interval fromTo further localize orexin expression within the central
nervous system, we performed in situ hybridization and 2±4 h postinjection was increased approximately 3-fold
with either dose as compared to vehiclecontrols. Humanimmunohistochemical analyses in rat brains. In situ hy-
bridization with a rat prepro-orexin cRNA probe in coro- orexin-B also significantly augmented food intake; at the
2 hr time point, we observed 5- and 12-fold stimulation ofnal sections showed orexin±containing neurons orga-
nized bilaterally and symmetrically in a discrete set in food consumption by 3 nmol and 30 nmol orexin-B,
respectively, as compared with vehicle controls (Figurehypothalamic and subthalamic areas of the adult rat
(C) Low magnification of section caudal to Figure 5A showing the distribution of prepro-orexin mRNA±containing neurons. Mammillothalamic
tract (mt), third ventricle (3V), cerebral peduncle (cp), infundibular stem (Infs). There are two groups of neurons: one group is seen in the
posterior hypothalamus (PH) and the other in the lateral hypothalamus (LH). The yellow rectagle indicates the field shown in Figure 5D.
(D) Higher magnification of the neuronal cell bodies in Figure 5C. The yellow vertical line indicates the boundary separating the medial neurons
of PH and the neurons of LH.
(E) Low magnification of prepro-orexin mRNA±containing neurons seen in parasagittal section traversing the posterior hypothalamic area
shown in Figure 5D. Cerebral cortex (CC), dentate gyrus (DG), splenium of the corpus callosum (scc), lateral ventricle (LV), caudate putamen
(Cpu), corpus callosum (cc), septum (S), anterior commissure (ac), thalamus (THAL), optic chiasm (ox), third ventricle (3V), pineal gland (Pi),
superior colliculus (SC), inferior colliculus (IC), cerebellum (Cb), and pontine nucleus (Pn). The yellow rectagle indicates the field magnified in
Figure 5F.
(F) High-magnification of the prepro-orexin±expressing neurons in the posterior hypothalamus (PH) shown in Figure 5E.
(G) Orexin-A-immunoreactive neurons in the LH of a frozen parasagittal section. Dorsal aspect is to the left side of this panel. The yellow box
corresponds to the field shown in Figure 5H. The staining of orexin-A-positive neurons was abolished in the presence of excess (100 nM)
synthetic orexin-A.
(H) High magnification of the immunoreactive orexin±containing neurons of the LH area. The boxed area of cells Figure 5G have been rotated
908 clockwise. In general, most of the neurons are multipolar, but a few are fusiform. The nucleus is not immunopositive, indicating that orexin
is cytoplasmic. Beaded neuronal processes are sometimes seen in these sections (arrowhead).
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Figure 6. Stimulation of Food Consumption
by Intracerebroventricular Injection of Or-
exin-A and -B in Freely Fed Rats
Designated amounts of synthetic human or-
exin-A (left) or -B (right) were administered in
a 5 ml bolus through a catheter placed in the
left lateral ventricle in early light phase. Cu-
mulative food consumption was plotted over
the period of 4 hr after injection. Asterisks
(*) indicate significant difference from vehicle
controls (p , 0.05, n 5 8±10, ANOVA followed
by Student-Newman-Keuls test). Crosses (²)
designate significant difference between 3
nmol and 30 nmol injections (p , 0.05, n 5
8±10, ANOVA followed by Student-Newman-
Keuls test). Similar results were obtained in
at least four independent sets of experiments.
The same vehicle control curve was replotted
in both panels.
6, right). The effects of orexin-B did not last as long as end of the 48 hr period, rats were sacrificed and the
thalamic/hypothalamic portion of the brain was dis-those of orexin-A; there was little stimulation of food
intake after 2 hr even with thehigher dose. These actions sected. Total RNA was extracted from individual sam-
ples and subjected to quantitative Northern blot analy-of orexin were less efficacious than NPY, a known orexi-
genic neuropeptide (Gerald et al., 1996; Turton et al., sis. After the 48 hr fast, hypothalamic prepro-orexin
mRNA was up-regulated 2.4-fold as compared with the1996), but longer lasting in the case of orexin-A; under
the same conditions, we found that 3 nmol human NPY fed control animals (Figure 7). NPY mRNA was pre-
viously described to be up-regulated under similarinduced cumulative food consumption of 11.4 6 2.0 g
and 12.8 6 1.8 g (mean 6 SEM) at 2 hr and 4 hr internals, fasted conditions (Qu et al., 1996). We also found that
NPY mRNA was up-regulated, albeit to a lesser extentrespectively, representing 24- and 14-fold stimulation
over vehicle controls. than the orexin mRNA (Figure 7A).
The shorter action of orexin-B as compared with or-
exin-A might be related to the fact that orexin-B is a
linear peptide with a free N terminus. In contrast, both Physiological Implications
Quantum leaps in our understanding of the mechanismstermini of orexin-A are blocked by posttranslational
modifications. Together with the two intrachain disulfide involved in the energy homeostasis have resulted from
the recent identification of the leptin signaling pathwaybonds, these modifications may render orexin-A resis-
tant to inactivating peptidases. We cannot exclude the (Zhang et al., 1994; Chen et al., 1996) and by additional
molecular genetic studies in mice. These studies havepossibility that these time courses reflect bona fide dif-
ferences in the biological actions of orexin-A and orexin-B revealed a number of central regulatory pathways medi-
atedby various neuropeptides (Yen et al.,1994; Ericksonin the central nervous system. The similar degrees of
stimulation of food intake by both orexin-A and orexin-B et al., 1996a; Huszar et al., 1997; Ohki-Hamazaki et al.,
1997). Maintenance of body weight is achieved by ansuggest that OX2R, thenonselective receptor (see Figure
3), may at least in part be involved in this in vivo pharma- intricate balance between energy intake (food consump-
tion) and expenditure. This energy homeostasis is ulti-cological action of orexins. However, more detailed in
vivo dose-response studies, as well as a separate block- mately governed by the brain, where a variety of afferent
signals reflect the animal's nutritional state and its ex-ade of these receptors either pharmacologically by se-
lective antagonists or genetically by gene targeting, will ternal environment, particularly food availability. These
signalsare integrated inorder tomoderate efferent path-be required to determine the receptor(s) involved.
ways that control feeding behavior and energy expendi-
ture (Bray, 1995; Rosenbaum et al., 1997). The afferentUp-Regulation of prepro-orexin mRNA
in the Fasting State signals include somatic sensory signals like smell and
taste, gastrointestinal signals like mechanical distentionThe stimulation of food intake by centrally administered
orexins suggested that these neuropeptides may play and chemical stimuli to the mucosa, blood-born metab-
olites like glucose and free fatty acids, and ªlipostaticºa physiological role in the central regulation of feeding.
To evaluate the possibility that orexin production and signals such as leptin (Friedman, 1997). Together with
the regulation of metabolic rate, which is in part medi-release may be affected by nutritional state, we com-
pared the level of prepro-orexin mRNA expression in ated by sympathetic and parasympathetic nervous sys-
tems and thyroid hormone, the regulation of feedingthe hypothalamus of fed and fasted rats. Adult male rats
were housed singly under 12 hr light-dark cycle for at behavior constitutes the efferent wing of energy homeo-
stasis. The central site of integration is thehypothalamusleast 5 days, and then either fed ad libitum (n 5 5) or
fasted for 48 hr starting at mid-light cycle (n 5 5). At the (Oomura, 1980; Bernardis and Bellinger, 1993, 1996),
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Figure 7. Up-Regulation of prepro-orexin mRNA in Fasted Rats
(A) Northern blot analysis of hypothalamic prepro-orexin mRNA expression in freely fed and 48 hr fasted rats. Each lane contains 20 mg of
total RNA from rat diencephalon. The membrane was rehybridized with NPY cDNA and then with b-actin cDNA as internal reference for the
amount of RNA loaded.
(B) Densitometric quantitation of Northern blot results presented in Figure 7A. The ratio of prepro-orexin and b-actin mRNA signals was
determined in each lane, and these normalized values were then compared between the fasted and fed groups. The mean value for normalized
prepro-orexin mRNA expression in the fed group was arbitrarily designated as unity.
where a large array of neurotransmitters, especially neu- causes the animal to eat less and lose weight, some-
times leading to death by starvation. While clearly over-ropeptides, modulate signals through complex neural
simplified, these hypotheses still provide a validconcep-circuits.
tual framework (Oomura, 1980).Recent molecular genetic studies in rodents have
Recent studies continue to reveal the molecular basisstarted to provide convincing evidence supporting im-
for the role of periventricular/medial hypothalamic re-portant roles for certain hypothalamic neuropeptides in
gions in energy homeostasis, e.g., ventromedial nu-the central regulation of energy balance (Wolf, 1997). For
cleus, arcuate nucleus, and paraventricular nucleus.example, NPY, which is negatively regulated by leptin
Neurons containing neuropeptides such as NPY (Bing(Zarjevski et al., 1993; Stephens et al., 1995; Tartaglia
et al., 1996), melanocortins (Jacobowitz and O'Donohue,et al., 1995), has been established as one of the positive
1978), glucagon-like peptide-1 (Shughrue et al., 1996),regulators of feeding behavior, presumably acting on the
and galanin (Warembourg and Jolivet, 1993), as well asY5 NPY receptor (Gerald et al., 1996); thus, the obesity of
the leptin and melanocortin-4 receptors (Mountjoy etleptin-deficient mice is partially ameliorated when they
al., 1994; Tartaglia et al., 1995) are abundant in oneare also deficient in NPY (Erickson et al., 1996b). Ectopic
or more of these periventricular/medial hypothalamicand constitutive expression of the endogenous antago-
regions. In contrast, few neuropeptides have been de-nist for melanocortin receptors, the Agouti protein, is
scribed to be produced chiefly in the lateral hypotha-the basis of obesity in obese-yellow mice (Yen et al.,
lamic regions. Other than the orexins, we are aware of1994; Fan et al., 1997), and, indeed, deficiency in the
only one distinct neurotransmitter that is specificallyMC4 melanocortin receptor completely replicates the
produced in the lateral hypothalamus: melanin concen-obesity syndrome of obese-yellow mice (Huszar et al.,
trating hormone (MCH) has been localized in the zona1997). Furthermore, Agouti-related protein (also termed
incerta and the lateral hypothalamic area (Bittencourt
ART), another endogenous antagonist for the MC4 re-
et al., 1992). Intriguingly, MCH was recently reported
ceptor, has recently been shown to be expressed in the
to stimulate food intake upon central administration.
hypothalamus, and the expression is up-regulated in
Moreover, MCH mRNA is up-regulated in ob/ob mice
ob/ob and db/db mice (Ollmann et al., 1997; Shutter et and by fasting in wild-type mice (Qu et al., 1996). It will
al., 1997). More recently, mice deficient for an orphan be important to investigate further the possible interplay
neuropeptide receptor (bombesin receptor type-3) have of orexin with this and otherpositive (e.g., Agouti-related
also been shown to become obese (Ohki-Hamazaki et protein, NPY, galanin, and opioids) and negative (e.g.,
al., 1997). Within the hypothalamus, two regions have leptin, melanocortins, corticotropin-releasing factor, glu-
traditionally been associated with the regulation of feed- cagon-like peptide-1, and cholecystokinin) regulators
ing and energy balance: the ventromedial hypothalamus of energy balance both within and outside the central
and the lateral hypothalamic area. A classical series nervous system (Arase et al., 1988; Rosenbaum et al.,
of lesion experiments led to the hypothesis that the 1997).
ventromedial hypothalamus functions as a ªsatiety cen- A decline of blood glucose levels can signal the initia-
ter,º whereas the lateral hypothalamic area works as a tion of food intake (Oomura, 1980). The lateral hypotha-
lamic area contains glucose-sensitive neurons that areªfeeding center.º Thus, a lateral hypothalamic lesion
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assayed. Step 4 (Figure 1D): the active peak was diluted 4-fold withactivated by glucopenia and thus implicated in the posi-
0.1% TFA and directly loaded onto the same C18 column, but thistive short-term regulation of feeding and energy expen-
time preequilibrated at 408C with 3% CH3CN/0.1% TFA. A 21%-36%diture (Oomura et al., 1974). It is tempting to speculate
gradient of CH3CN in 0.1% TFA was applied over 75 min at 408C.that all or some of the orexin-containing neurons may be The major 210 nm peak, representing virtually pure orexin-A, was
glucose-sensitive, or that they may receive stimulatory collected manually. For purification of rat orexin-B and orexin-B[3±
28] as well as bovine orexin-A, basically the same procedures wereprojections from glucose-sensitive neurons. Future ex-
used, except that step 3 was replaced with a reverse-phase HPLCperiments will also determine whether orexins have ad-
under neutral pH: active fractions from step 2 were directly loadedditional actions relevant to nutritional homeostasis, such
onto thesame analytical C18 column preequilibrated with 3% CH3CN/as effects on the regulation of systemic energy expendi-
20 mM Tris-HCl (pH 7.0 at 408C). A 3%±40% gradient of CH3CN in
ture, secretion of metabolic hormones such as insulin, 20 mM Tris-HCl (pH 7.0) was applied over 74 min at 408C. Individual
and ultimately, the regulation of body weight. 210 nm peaks were collected manually, and the active fraction was
subjected to step 4 as described above.The present discovery of orexins and their receptors
may provide a novel molecular basis for the role of the
Peptide Microsequencinglateral hypothalamic areas in the regulation of feeding
Direct sequencing of the intactorexin-A peptide by Edman degrada-behavior. It is clear, however, that the definitive assign-
tion failed, suggesting a blocked amino terminus. The monoisotopicment of physiological roles for orexins requires further molecular mass of the intact peptide was determined to be 3558.7 6
pharmacological as well as molecular genetic investiga- 0.1 Da by time lag±focusing matrix-assisted laser desorption/ioniza-
tions. Nevertheless, pharmacological intervention di- tion (MALDI) mass spectrometry (Carr and Annan, 1996) using inter-
nal peptide standards (Micromass TofSpec-SE). The measuredrected at the orexin receptors may prove to be an attrac-
mass of the peptide increased by 232 Da upon reaction with iodo-tive avenue toward the discovery of novel therapeutics
acetamide in the presence of DTT, indicating the presence of twofor diseases involving disregulation of energy homeo-
intramolecular disulfides bonds. Digestion of the reduced and alkyl-stasis, such as obesity and diabetes mellitus.
ated peptide with Lys-C provided two peptides with average Mr 5
1287 and 2530. Edman sequence of the mixture provided a single
Experimental Procedures partial sequence of TCSCRLYELLHGAGNHAAG. Edman sequence
analysis of an Asn-C digest mixture extended the C-terminal se-
Transfected Cells quence as follows . . . HAAGILTL.The C-terminal sequence, . . . EXX
Full-length cDNAs encoding individual orphan GPCRs were sub- HGAGNHAAGXXTX (where X is either Leu or Ile), was also confirmed
cloned into the pCDN mammalian expression vector. These plas- by MALDI mass spectrometry of the peptide partially digested with
mids were individually transfected into the human embryonic kidney carboxypeptidase Y (Voyager Elite XL, PerSeptive Biosystems). The
(HEK) 293 cells, and stable transfectant cell lines established and blocked N-terminal Lys-C peptide was sequenced by nanoelectro-
maintained as described (Aiyar et al., 1994). For in vitro pharmaco- spray collision induced dissociation (CID) tandem mass spectrome-
logical assessments (Figure 3), CHO-K1 cells were stably trans- try (Carr et al., 1996; Wilm and Mann, 1996) on a triple quadrupole
fected with human OX1R and OX2R expression vectors, and mass spectrometer (Perkin-Elmer Sciex API-III). A sequence of
transfected cell lines were maintained as previously described (Xu ,EPXPDCCRQK (calculated MH1 5 1286.6) was determined from
et al., 1994). the tandem MS data, where ,E is pyroglutamic acid, and X is either
Leu or Ile. The identity and sequence of the first two residues were
confirmed by MS3 of the b2 ion produced by in-source CID. X wasPurification of Orexin
determined to be Leu by amino acid analysis of the HPLC purifiedApproximately 200 g of frozen rat whole brain (150 pieces, Pel-
N-terminal peptide. The Gln residue at position 9 was distinguishedFreeze) were homogenized by Polytron in 10 3 volume of 70% (v/v)
from Lys (both amino acids have the same residue mass) by acetyla-acetone, 1 M acetic acid, and 20 mM HCl. The homogenate was
tion of the peptide and remeasurement of the molecular weight. Thecentrifuged at 20,000 3 g for30 min at 48C. The resultant supernatant
MH1 ion for the ligand shifted by 42 Da from 1286.6 to 1328.6,was collected and extracted three times with diethyl ether. The
indicating the addition of only one acetate group (calculated MH1 5aqueous phase was centrifuged at 20,000 3 g for 30 min at 48C,
1328.6). Because Gln residues cannot be acetylated and the N termi-and the supernatant was loaded onto two 10 g cartridges of Sep-
nus is blocked, the addition of only one acetate group stronglyPak C18 (Waters), which were preequilibrated with 0.1% (v/v) TFA.
suggests the C-terminal sequence is QK, not KK. The Mr determinedCartridges were washed with 5% CH3CN/0.1% TFA, and then eluted
for the intact peptide (3558.7 6 0.1 Da) indicates that the C terminuswith 50% CH3CN/0.1% TFA. The eluate was lyophilized, redissolved
is an amide rather than a free acid and that all four Cys are inin 1 M acetic acid with sonication, and then filtered through a 20
disulfide linkages (calculated monoisotopic Mr 5 3558.7).mm Mirex GV filter (Millipore). Step 1 (Figure 1A): the extract was
directly loaded onto a C18 reverse-phase HPLC column (Vydac
218TP510; 10 mm 3 250 mm), preequilibrated with 3% CH3CN/0.1% Cloning of Rat prepro-orexin cDNA
A part of the orexin-A sequence, QPLPDCCRQKTCSCRLYELLHGATFA at a flow rate of 3 ml/min at room temperature. A 10%±40%
gradient of CH3CN in 0.1% TFA was then applied over 100 min. GNHAAGI (amino acids 1±30), was chosen to design highly degener-
ate oligonucleotide primers encoding its ends: 59-CA(A,G)CCN(C,T)TThree-milliliter fractions were collected, and ≈2% of each fraction
was set aside and assayed for [Ca21]i transients in OX1R±expressing NCCNGA(C,T)TG(C,T)TG-39 and 59-ATNCCNGCNGC(A,G)TG(A,G)TT-
39. A cDNAfragment correctly encoding the peptide was obtained byHEK293 cells (see below). Step 2 (Figure 1B): the active fractions
were pooled and directly applied to a cation-exchange HPLC col- RT±PCR using rat brain poly(A) RNA as template. A nondegenerate
oligonucleotide primer, 59-GTTGCCAGCTCCGTGCAACAGTTCGTAumn (TosoHaas SP-5PW; 7.5 mm 3 75 mm) preequilibrated with 20
mM Na-phosphate (pH 3.0)/30% CH3CN at room temperature. A GAGACGG-39, was designed based on the sequence of the RT±PCR
product. Double-stranded cDNA was synthesized from rat brain0±0.5 M gradient of NaCl in 20 mM Na-phosphate (pH 3.0)/30%
CH3CN was applied over 60 min at a flow rate of 1 ml/min. One- poly(A) RNA, ligated to the Marathon adaptor (Clontech), and used
as template for the initial 59-RACE reaction with Adaptor Primer 1milliliter fractions were collected, and z3% from each fraction was
used for the [Ca21]i assay. Step 3 (Figure 1C): the active fractions (Clontech) and the above specific primer. A nested PCR reaction
was performed using an oligonucleotide, 59-CGGCAGGAACACGTCwere pooled, diluted 4-fold with 0.1% TFA, and directly loaded onto
an analytical C18 reverse-phase column (Vydac 218TP54; 4.6 mm 3 TTCTGGCG-39, and the Adaptor Primer 2 (Clontech). An approxi-
mately 250 bp 59 cDNA product, correctly encoding the peptide,250 mm) preequilibrated with 3% CH3CN/0.1% TFA at a flow rate
of 1 ml/min at room temperature. A 21%±36% gradient of CH3CN was obtained. Single-stranded rat brain cDNA was then synthesized
using an oligonucleotide, 59-CCTCTGAAGGTTCCAGAATCGATAGin 0.1% TFA was applied over 75 min. Individual UV absorption peaks
(210 nm) were collected manually, and z3% from each fraction was (T)25(A,C,G)N-39, as a specific primer for the reverse transcription.
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This was used as template for a 39-RACE reaction using a specific [125I]orexin-A plus designated concentrations of unlabeled competi-
tors. Cells were then washed three times with ice-cold phosphate-primer, 59-TCCTTGGGTATTTGGACCACTGCACCGAAG-39 (corre-
sponding to a part of the 59-noncoding region of the cDNA sequence buffered saline, lysed in 0.1 N NaOH, and cell-bound radioactivity
was determined by a g-counter.obtained by the 59-RACE), and an anchor primer, 59-CCTCTGAAGGT
TCCAGAATCGATAG-39. The product was subjected to a nested
PCR reaction using an oligonucleotide, 59-ATACCATCTCTCCGGAT Intracellular Calcium Transient Assay
TGCCTCTCCCTGA-39, and the same anchor primer. A discrete Stable transfectant HEK293 cells expressing orphan GPCRs were
0.6 kb product containing the correct 59 cDNA sequence was ob- loaded with Fura-2 AM in suspension, and [Ca21]i transients evoked
tained. The full-length cDNA sequence was determined by rese- by agonists were monitored by a Model CAF-110 Intracellular Ion
quencing the products obtained from three independent 39-RACE Analyser (JASCO) in 500ml cuvette as previously described (Grynkie-
reactions. wicz et al., 1985; Xu et al., 1994). For in vitro pharmacological charac-
terization (Figure 3), the same procedures were performed using
stably transfected CHO cells expressing human OX1R or OX2R.
Cloning of Human and Mouse prepro-orexin Genes
Since we found that the full-length rat prepro-orexin cDNA, which In Situ Hybridization
contains CTG triplet repeats (encoding the oligo-leucine stretch in A 0.29 kb segment of rat cDNA encoding Gln33-Ser128 of prepro-
the signal sequence), tends to cross-hybridize with a number of orexin was generated as described above and subcloned into
unrelated genes, we produced a cDNA probe that did not contain pBluescript II SK(1) vector. Sense and anti-sense riboprobes were
the repeats by RT±PCRfrom rat brain RNA, using primers 59-CAGCC generated with T7 and T3 RNA polymerases, respectively, using the
TCTGCCCGACTGCTGT-39 and 59-CGTCTTTATTGCCTAGGGACTG Maxiscript kit (Ambion) in the presence of 35S-CTP (Amersham).
GCGAGGAG-39. Human and mouse genomic libraries (Clontech and In situ hybridization to adult rat brain sections was performed as
Stratagene, respectively) were screened by plaque hybridization to described (Benjamin et al., 1997).
this cDNA probe. Resulting genomic fragments containing the entire
prepro-orexin coding sequences were further characterized and Immunohistochemistry
sequenced by standard procedures. Anti-orexin-A antiserum was raised in rabbits by immunization with
synthetic orexin-A[14±33], CRLYELLHGAGNHAAGILTL-amide, con-
jugated to keyhole limpet hemocyanin (Calbiochem) using 3-malei-Cloning of OX1R and OX2R cDNAs midobensoic acid N-hydroxysuccimide ester (Sigma). AntiserumCloning of full-length human OX1R (HFGAN72) cDNA has been dis- was affinity purified on an orexin-A-conjugated Sepharose CL-4Bclosed elsewhere (US Patent No. WO96/34877; November 7, 1996)
(Pharmacia) column and used for immunohistochemistry. Male(Figure 2C). Rat OX1R cDNA was obtained by screening rat brain Sprague-Dawley rats (z300 g) were anesthetized and perfused viacDNA libraries with the full-length human OX1R cDNA as probe, the left cardiac ventricle with phosphate-buffered saline (PBS). Brainusing standard procedures. In order to clone full-length human OX2R was taken out, directly embedded in OCT compound (Tissue-Tek),cDNA, an inter-EST RT±PCR was performed with human brain
and frozen in liquid nitrogen. Cryostat sections (15 mm) were cutpoly(A)1 RNA as template, using oligonucleotide primers based on
and mounted on silane-coated glass sides. The sections were post-the public 59 and 39 EST sequences (GenBank accession numbers
fixed with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.2)D81887 and W86548, respectively). The resultant cDNA product,
for 1 hr and washed three times in PBS. The sections were incubatedwhich contained a large part of the coding region spanning the
with 1% bovine serum albumin in PBS for 1 hr and then incubatedtransmembrane domains 1±7, was further extended by standard 59-
with affinity-purified antiserum in the same solution for 1 hr at roomRACE and 39-RACE procedures. Rat OX2R cDNA was obtained by
temperature. After washing three times in PBS, the sections werescreening rat brain cDNA libraries with the full-length human OX2R
incubated with FITC-conjugated goat anti-rabbit IgG antibody (Cap-cDNA as probe.
pel) for 1 hr at room temperature. Slides were then washed three
times in PBS and examined under fluorescence microscope.
Radiation Hybrid Mapping
Intracerebroventricular Administration of OrexinsThe following oligonucleotides were used to amplify genomic frag-
Male Wistar rats (180±200 g on arrival; Charles-River) were housedments: prepro-orexin, GCCAAAGGTGTCTCCACTC and GACAGGT
under controlled lighting (12 hr light-dark cycle) and temperatureGCAAACGGAGCAC; OX1R, GGTGCTCACCAGCGTCACCAC and
(228C) conditions. Food (standard chow pellets) and water wereGCTTAATCCTCACATCAACCCTGC; OX2R, GAGGAGCTTGCAGCAT
available ad libitum. Rats (200±220 g) were anesthetized with pento-TGAGC and GTGCAGGTATTCCCTCCACAG. PCR of the prepro-
barbital (50 mg/kg i.p.), positioned in a Koph Model 900 stereotaxicorexin, OX1R, and OX2R genes was performed in duplicates against
frame, and implanted with a guide cannula into the left lateral ventri-the 96 samples (including 3 controls: donor DNA, host DNA, and
cle under sterile conditions using a MEDIBIO Optical Brain Tracerwater) in the GeneBridge 4 radiation hybrid panel (Research Genet-
(Muromachi Kikai) (Ikeda and Matsushita, 1980). The coordinatesics) (Gyapay et al., 1996). The scoring strings of 93 3 1's (presence),
used to map the correct positioning of the implants were: 6.1 mm0's (absence), and 2's (ambiguous) were submitted to the Radiation
anterior to the lambda, 1.5 mm lateral from the midline, and z3.4Hybrid Mapping Server at MIT (http://www.genome.wi.mit.edu/)
mm (guided by MEDIBIO) ventral to the skull surface, with the incisor(Hudson et al., 1995). Cytogenetic locations were inferred from these
bar set 3.3 mm below the interauricular line. Rats were then housedresults using the markers shown to neighbor the genes via The
singly under the same conditions as above for a recovery period ofGenome Directory (1995), and GDB (http://gdbwww.gdb.org/gdb/
at least 7 days, and body weights were monitored daily for thedocs/gdbhome.html). Chromosomal locations were confirmed by
duration of the study. After recovery from surgery, rats were trans-PCR on the BIOS panel (BIOS, USA) using the same oligo pairs and
ferred to grid-floor cages and fed with powdered chow so that foodconditions.
intake measurements could be made. The rats were acclimated to
the new environment at least for 1 day. The position of the cannula
was verified by central administration of human NPY (3 nmol inRadioligand Binding Assay
Synthetic human orexin-A was 125I-labeled at Tyr17 by Chlora- sterile water); for a positive test, at least 8 g of food was eaten over
a 4 hr period postinjection. Only positively testing animals (n 5 8±10)mine-T oxidation in the presence of Na125I (2,000 Ci/mmol, New
England Nuclear), and monoiodinated peptide was purified by C18 were used. The studies were conducted according to a multidose,
crossover design, with the order of dosing determined using thereverse-phase HPLC as described (Takigawa et al., 1995). Stable
transfectant CHO cell lines expressing human OX1R or OX2R were Latin square principle, leaving at least one rest day between admin-
istrations. All doses were delivered in a volume of 5 ml in sterileeach seeded onto 12-well plates at a density of 3 3 105 cells per
well. After an overnight culture, medium was discarded and cells water over 30 s, and the injector remained in position for a further
30 s to ensure complete dispersal of the peptide. All intracerebro-were incubated at 208C for 90 min with binding buffer (HEPES-
buffered saline/0.5% bovine serum albumin) containing 10210 M ventricular administrations began at 2 h into light cycle, and food
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intake was measured at 1, 2, and 4 h intervals. All peptides were Eipper, B.A., Milgram, S.L., Husten, E.J., Yun, H.Y., and Mains, R.E.
(1993). Peptidylglycine alpha-amidating monooxygenase: a multi-dissolved in sterile water, initially at 6 mM, and diluted in water as
needed. Water alone was used for the vehicle control. functional protein with catalytic, processing, and routing domains.
Protein Sci. 2, 489±497.
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